3 months MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal Cancer Zacks
The LEAP-015 study is evaluating Merck’s Keytruda and Eisai’s Lenvima plus chemotherapy in certain types of gastroesophageal adenocarcinoma.
XThe LEAP-015 study is evaluating Merck’s Keytruda and Eisai’s Lenvima plus chemotherapy in certain types of gastroesophageal adenocarcinoma.
XThe Stock Market News is a financial news aggregator for traders and investors that proposes to you the latest breaking news headlines on global financial markets, economy and business. Live qoute and chart technical analysis, opinion, price forecast on current stock market, currencies (Forex), cryptocurrency, commodities futures, ETFs, funds, bonds and more. Disclaimer: by using any material of this website, you acknowledge and agree that TheStockMarketNews.com is not responsible for the content, actions or any legal issues arising from third-party websites; materials of this website are not financial advice or call to actions. Trading and investing in financial instruments involve high risks including the risk of investment loss.